A Phase Ib/IIa Randomized, Controlled Dose Escalation Study to Evaluate Safety, Tolerability, and Antiviral Activity of BRII-179 (VBI-2601) among Subjects with Chronic Hepatitis B
Phase of Trial: Phase I/II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs VBI 2601 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Proof of concept
- Sponsors Brii Biosciences
- 14 Nov 2019 According to VBI Vaccines media release, results from this study are expected in the second half of 2020.
- 14 Nov 2019 According to VBI Vaccines media release, first patient dosed in this trial.
- 06 Nov 2019 According to VBI Vaccines media release, VBI and Brii Bio plan to initiate the enrolment later in Q4 2019, which would enable an initial data readout in the second half of 2020.